Huateng Pharma Supplies Anti-diabetic API Intermediates With Huge Stock

CHANGSHA, China - July 27, 2023 - PRLog -- Diabetes is a serious chronic disease characterized by elevated blood sugar concentrations associated with the effects of abnormal beta cell biology on insulin action. Diabetes occurs when the pancreas does not produce enough insulin or the body does not use the insulin it does produce efficiently.

The most common forms of diabetes are type 1 diabetes and type 2 diabetes. Type 1 diabetes is characterized by insufficient insulin production and the need for daily insulin intakes, and it is unclear what causes it. More than 95 percent of people with diabetes have type 2 diabetes, which is characterized by the body's abnormal use of insulin that affects the body's use of glucose for energy, mainly due to obesity, physical inactivity and genetics.

Type 1 diabetes is treated with insulin injections. The majority of diabetic patients are obesity-induced patients, that is, type 2 diabetes patients. Type 2 diabetes mainly uses hypoglycemic drugs to control blood sugar, and often requires life-long medication, such as metformin, sulfonylureas, or sodium-glucose cotransporter type 2 (SGLT-2) inhibitors (https://us.huatengsci.com/news/show/1602.html), etc. If the islet function is reduced or insulin secretion is too low, insulin injection therapy also needs to be considered. Non-drug-assisted treatment of type 2 diabetes is mainly diet control and exercise. Most type 2 diabetes is caused by obesity. Obese people have abnormal fat distribution and excessive accumulation, which will lead to insulin resistance and overload the pancreas. Weight loss can be used to regulate lipid metabolism, thereby affecting glucose metabolism, and repairing lipid metabolism to achieve the goal of balancing glucose metabolism.

Huateng Pharma is a professional pharmaceutical intermediates (https://us.huatengsci.com/product/175.html) supplier. It can provide anti-diabetic drugs intermediates such as semaglutide intermediates, canagliflozin intermediates, dapagliflozin intermediates, empagliflozin intermediates for customers' research.

Canagliflozin Intermediates:

(5-Bromo-2-methylphenyl)[5-(4-fluorophenyl)-2-thienyl]methanone
CAS NO.1132832-75-7

2-(4-Fluorophenyl)-5-[(5-iodo-2-methylphenyl)methyl]thiophene
CAS NO.898566-17-1

2-[(5-bromo-2-methylphenyl)methyl]-5-(4-fluorophenyl)thiophene
CAS NO.1030825-20-7

2-(4-Fluorophenyl)thiophene
CAS NO.58861-48-6

2-Methyl-5-bromobenzoic acid
CAS NO.79669-49-1

Semaglutide Intermediates:

CH2COOH-PEG2-NH2.HCl
CAS NO.: 134979-01-4

Fmoc-L-Lys[Oct-(otBu)-Glu-(otBu)-AEEA-AEEA]-OH
CAS NO.1662688-20-1

Boc-NH-PEG2-CH2COOH
CAS NO.: 108466-89-3

NH2-PEG2-CH2COOH
CAS NO.: 134978-97-5

Octadecanedioic acid
CAS NO.871-70-5

Dapagliflozin Intermediates:

4-Iodo-1-chloro-2-(4-ethoxybenzyl)benzene
CAS NO.1103738-29-9

Benzene, 4-bromo-1-chloro-2-[(4-ethoxyphenyl)methyl]-
CAS NO.461432-23-5

Empagliflozin Intermediates:

(3S)-3-[4-[(5-bromo-2-chlorophenyl)methyl]phenoxy]oxolane
CAS NO.915095-89-5

(S)-4-iodo-1-chloro-2-(4-tetrahydrofuran-3-yloxy-benzyl)-benzene
CAS NO.915095-94-2